Kenalog and Bursitis infective - a phase IV clinical study of FDA data

Summary:

Bursitis infective is reported as a side effect among people who take Kenalog (triamcinolone acetonide), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Dilaudid, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Bursitis infective when taking Kenalog. It is created by eHealthMe based on reports of 10,533 people who have side effects when taking Kenalog from the FDA, and is updated regularly.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

What is Bursitis infective?

Bursitis infective (the bursa can become infected, this is called infected bursitis) is found to be associated with 118 drugs and 161 conditions by eHealthMe. Check the latest studies of Bursitis infective.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

10,533 people reported to have side effects when taking Kenalog.
Among them, 56 people (0.53%) have Bursitis infective.

Among these 56 people:

How long have people been on Kenalog when they have Bursitis infective? *

What is the gender of people who have Bursitis infective when taking Kenalog? *

female: 98.18 %
male: 1.82 %

What is the age of people who have Bursitis infective when taking Kenalog? *

What are other drugs people take besides Kenalog? *

What are other side effects people have besides Bursitis infective? *

Pneumonia: 53 people, 94.64%
Localised Infection (infection at the single location): 53 people, 94.64%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 53 people, 94.64%
Staphylococcal Infection (an infection with staphylococcus bacteria): 52 people, 92.86%
Skin Ulcer: 52 people, 92.86%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 52 people, 92.86%
Osteoporosis (bones weak and more likely to break): 47 people, 83.93%
Peripheral Vascular Disorder: 47 people, 83.93%
Infection: 45 people, 80.36%
Skin Discoloration: 42 people, 75.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 53 people, 94.64%
Diabetes: 17 people, 30.36%
Abdominal Pain Upper: 12 people, 21.43%
Phantom Pain: 5 people, 8.93%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 2 people, 3.57%
Joint Pain: 2 people, 3.57%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 1.79%
Gastric Ulcer (stomach ulcer): 1 person, 1.79%

* Approximation only. Some reports may have incomplete information.

Do you take Kenalog and have Bursitis infective?

- Check whether Bursitis infective is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kenalog:

Kenalog (10,692 reports)

Browse all side effects of Kenalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bursitis infective:

Bursitis infective (118 drugs)

Browse all the conditions that are associated with Bursitis infective:

Bursitis infective (161 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide (the active ingredients of Kenalog) and Kenalog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.